Our study found that high expression of TP53, ACLY, THBS1 and YARS was associated with worse overall survival (OS) in breast cancer patients (Figure 6B); while low expression of JUN, PPARG and IMPDH2 was associated with worse OS in breast cancer patients; while expression of CAD, IL6 and CXCL8 was not associated with OS in breast cancer patients (CAD, p = 0.27. Here, IMPDH2 is linked to breast carcinoma.